New WHO INN for cell-based and gene-based substances: timing, usage, and simplicity

Affiliations

¹ Department of Health, Therapeutic Goods Administration, Woden, Canberra, ACT, Australia.
² INN Programme and Classification of Medical Products, INN/HPS/MHP, WHO, Geneva 1211, Switzerland.
³ Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences, University Hospital of Modena and Reggio Emilia, Modena, Italy.
⁴ Largs, UK.
⁵ INN Programme and Classification of Medical Products, INN/HPS/MHP, WHO, Geneva 1211, Switzerland. Electronic address: baloccor@who.int.

Tony Manderson et al. Lancet. 2024.

. 2024 Oct 5;404(10460):1302-1303.

doi: 10.1016/S0140-6736(24)01858-0.

¹ Department of Health, Therapeutic Goods Administration, Woden, Canberra, ACT, Australia.
² INN Programme and Classification of Medical Products, INN/HPS/MHP, WHO, Geneva 1211, Switzerland.
³ Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences, University Hospital of Modena and Reggio Emilia, Modena, Italy.
⁴ Largs, UK.
⁵ INN Programme and Classification of Medical Products, INN/HPS/MHP, WHO, Geneva 1211, Switzerland. Electronic address: baloccor@who.int.

No abstract available

Publication types